Targets › TGFBR1
6 programs from 6 companies in 7 trials: 3 Phase 1, 3 Phase 2, 1 Phase 3; Oncology; next expected readout Dec 2026.
Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic…. (UniProt, P36897)
Open in Phaseline: the race on TGFBR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | IMM01 (timdarpacept) ALK5/TGF-β receptor inhibitor | TGFBR1 | Phase 3 | Chronic Myelomonocytic Leukemia | Oct 2029 |
| Providence Health & Services | Galunisertib (LY2157299) TGF-beta receptor type I inhibitor | TGFBR1 | Phase 2 | Rectal Adenocarcinoma | Dec 2026 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Galunisertib (LY2157299) TGF-beta receptor type I inhibitor | TGFBR1 | Phase 2 | Prostate Cancer | Dec 2026 |
| The Netherlands Cancer Institute | Galunisertib TGF-beta receptor type I inhibitor | TGFBR1 | Phase 1 | Colorectal Cancer Metastatic | Dec 2026 |
| MedPacto | Vactosertib TGF-beta receptor type I inhibitor | TGFBR1 | Phase 1 | Osteosarcoma; Adenocarcinoma Esophagus | Dec 2027 |
| M.D. Anderson Cancer Center | Tasquinimod TGF-β receptor type I (ALK5) inhibitor | TGFBR1 | Phase 1 | Primary Myelofibrosis | May 2029 |
Chronic Myelomonocytic Leukemia (1) Primary Myelofibrosis (1) Osteosarcoma (1) Adenocarcinoma Esophagus (1) Rectal Adenocarcinoma (1) Colorectal Cancer Metastatic (1) Prostate Cancer (1)
small molecule (5), mixed (1)
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1) M.D. Anderson Cancer Center (1) MedPacto (1) Providence Health & Services (1) The Netherlands Cancer Institute (1) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.